Rigerna
About:
Rigerna develops unique small nucleic acid medicines and innovative nucleic acid therapies for nonliver tissues.
Top Investors: GSR United Capital, Shanghai Science and Technology Investment, Trinity Innovation Fund, Xincheng Private Equity, Yuanxi Haihe Fund
Description:
Rigerna develops unique small nucleic acid medicines and innovative nucleic acid therapies for nonliver tissues.
Total Funding Amount:
100M CNY
Headquarters Location:
Fengtai, Beijing, China
Founded Date:
2022-01-01
Contact Email:
info(AT)rigerna.com
Founders:
Number of Employees:
11-50
Last Funding Date:
2024-10-21
IPO Status:
Private
Industries:
© 2025 bioDAO.ai